MRK Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 18.95% compared to Merck &'s net margin of 11.99%. Merck &'s return on equity of 29.26% beat Johnson & Johnson's return on equity of 20.88%.

Merck & has a consensus price target of $127.73, signalling upside risk potential of 27.92%. On the other hand Johnson & Johnson has an analysts' consensus of $171.66 which suggests that it could grow by 20.66%. Given that Merck & has higher upside potential than Johnson & Johnson, analysts believe Merck & is more attractive than Johnson & Johnson.

Merck & has a beta of 0.390, which suggesting that the stock is 60.989% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.607%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.13%. Johnson & Johnson offers a yield of 3.45% to investors and pays a quarterly dividend of $1.24 per share. Merck & pays 2039.73% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Merck & quarterly revenues are $16.7B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Merck &'s net income of $3.2B is higher than Johnson & Johnson's net income of $2.7B. Notably, Merck &'s price-to-earnings ratio is 20.93x while Johnson & Johnson's PE ratio is 23.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 4.02x versus 3.94x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 18.95% compared to Merck &'s net margin of 8.48%. Merck &'s return on equity of 29.26% beat Eli Lilly and's return on equity of 66.4%.

Merck & has a consensus price target of $127.73, signalling upside risk potential of 27.92%. On the other hand Eli Lilly and has an analysts' consensus of $984.05 which suggests that it could grow by 25%. Given that Merck & has higher upside potential than Eli Lilly and, analysts believe Merck & is more attractive than Eli Lilly and.

Merck & has a beta of 0.390, which suggesting that the stock is 60.989% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.729%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.13%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.30 per share. Merck & pays 2039.73% of its earnings as a dividend. Eli Lilly and pays out 77.65% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Merck & quarterly revenues are $16.7B, which are larger than Eli Lilly and quarterly revenues of $11.4B. Merck &'s net income of $3.2B is higher than Eli Lilly and's net income of $970.3M. Notably, Merck &'s price-to-earnings ratio is 20.93x while Eli Lilly and's PE ratio is 85.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 4.02x versus 17.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 18.95% compared to Merck &'s net margin of 0.7%. Merck &'s return on equity of 29.26% beat Moderna's return on equity of -17.44%.

Merck & has a consensus price target of $127.73, signalling upside risk potential of 27.92%. On the other hand Moderna has an analysts' consensus of $73.64 which suggests that it could grow by 70.59%. Given that Moderna has higher upside potential than Merck &, analysts believe Moderna is more attractive than Merck &.

Merck & has a beta of 0.390, which suggesting that the stock is 60.989% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.13%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & pays 2039.73% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Merck & quarterly revenues are $16.7B, which are larger than Moderna quarterly revenues of $1.9B. Merck &'s net income of $3.2B is higher than Moderna's net income of $13M. Notably, Merck &'s price-to-earnings ratio is 20.93x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 4.02x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 18.95% compared to Merck &'s net margin of 25.23%. Merck &'s return on equity of 29.26% beat Pfizer's return on equity of 4.63%.

Merck & has a consensus price target of $127.73, signalling upside risk potential of 27.92%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.3%. Given that Merck & has higher upside potential than Pfizer, analysts believe Merck & is more attractive than Pfizer.

Merck & has a beta of 0.390, which suggesting that the stock is 60.989% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Merck & has a quarterly dividend of $0.81 per share corresponding to a yield of 3.13%. Pfizer offers a yield of 6.26% to investors and pays a quarterly dividend of $0.42 per share. Merck & pays 2039.73% of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & quarterly revenues are $16.7B, which are smaller than Pfizer quarterly revenues of $17.7B. Merck &'s net income of $3.2B is lower than Pfizer's net income of $4.5B. Notably, Merck &'s price-to-earnings ratio is 20.93x while Pfizer's PE ratio is 36.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & is 4.02x versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.